Dataset Information

Lutetium ultraphosphate.

ABSTRACT: The structure of the title compound, LuP(5)O(14), comprises puckered eight-membered PO(4) rings linked by the lutetium cations in a complex way, forming a three-dimensional framework. Each eight-membered phosphate ring shares a bridging tetra-hedron with each of four adjacent tetra-hedra, to form layers of PO(4) tetra-hedra. These layers are c/2 in thickness and parallel to the ab plane. Each Lu ion is contained in one such layer, forming bonds to six O atoms in that layer and also to one O atom belonging to a tetra-hedron in each of the layers lying above and below it. The LuO(8) polyhedra are isolated from one another, since they share no common atoms. The Lu ions lie on twofold axes (special position 4e) and the shortest Lu?Lu distance is 5.703?(1)?Å.

SUBMITTER: Horchani-Naifer K

PROVIDER: S-EPMC2961625 | biostudies-literature | 2008 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Lutetium ultraphosphate.

Horchani-Naifer Karima K Férid Mokhtar M

Acta crystallographica. Section E, Structure reports online 20080510 Pt 6

The structure of the title compound, LuP(5)O(14), comprises puckered eight-membered PO(4) rings linked by the lutetium cations in a complex way, forming a three-dimensional framework. Each eight-membered phosphate ring shares a bridging tetra-hedron with each of four adjacent tetra-hedra, to form layers of PO(4) tetra-hedra. These layers are c/2 in thickness and parallel to the ab plane. Each Lu ion is contained in one such layer, forming bonds to six O atoms in that layer and also to one O atom ...[more]

PMID: 21202435

Similar Datasets

Project description:BackgroundLutetium 177 (177Lu) - DOTATATE is a form of peptide receptor radionuclide therapy (PRRT) utilized in the treatment of neuroendocrine tumors. Data on 177Lu-DOTATATE-induced thyroid dysfunction is limited.Case descriptionA 29-year-old male with SDHB positive metastatic paraganglioma enrolled under the 177Lu-DOTATATE trial (NCT03206060) underwent thyroid function test (TFT) evaluation comprised of thyroid stimulating hormone (TSH) and free thyroxine (FT4) immunoassay measurements per protocol prior to 177Lu-DOTATATE therapy. The TSH was suppressed [<0.01 µIU/ml (0.27-4.2 µIU/ml)], and FT4 was normal [1.3 ng/dl (0.9-1.7 ng/dl)]. The TSH receptor antibody and thyroid stimulating immunoglobulin index were undetectable [<1 IU/L (≤1.75 IU/L), and <1 (≤1.3) respectively], while the anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) antibodies were elevated [605 IU/ml (0.0-34.9 IU/ml), and 178 IU/ml (0.0-40.0 IU/ml) respectively]. Mass spectrometry on a stored (-80°C) plasma sample obtained one-month pre-PRRT revealed elevated total triiodothyronine (TT3) [235 ng/dl (65-193 ng/dl)] and FT4 [3.9 ng/dl (1.2-2.9 ng/dl)] levels. The patient was diagnosed with Hashimoto's thyrotoxicosis. However, the patient was asymptomatic. One month after the first dose of 200mCi 177Lu-DOTATATE, the patient noted fatigue and a 2.6 Kg weight gain. The TSH (73.04 µIU/ml), anti-TPO antibodies (>1,000 IU/ml), and anti-Tg antibodies (668 IU/ml) had substantially increased, with reductions in FT4 (0.3 ng/dl) and TT3 [54 ng/dl (87-169 ng/dl)]. Diagnostic gallium 68 - DOTATATE positron emission tomography-computed tomography performed prior to 177Lu-DOTATATE treatment revealed diffuse thyroid uptake. Post-therapy single-photon emission computed tomography also revealed diffuse uptake of 177Lu-DOTATATE in the thyroid gland. Levothyroxine therapy was initiated, and the patient's symptoms resolved.SummaryWe report, for the first time, a patient with asymptomatic primary hyperthyroidism who rapidly developed symptomatic primary hypothyroidism 1 month after 177Lu-DOTATATE therapy, accompanied by marked changes in TFTs and thyroid auto-antibody titers, with functional imaging evidence of diffuse uptake of 177Lu-DOTATATE in the thyroid gland.ConclusionsThyroid dysfunction can be associated with PRRT. Thyroid uptake patterns on pre-treatment diagnostic somatostatin analog scans might predict individual susceptibility to PRRT-associated TFT disruption. Therefore, periodic evaluation of TFTs should be considered in patients receiving PRRT.

Dataset Information

Lutetium ultraphosphate.

Publications

Lutetium ultraphosphate.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets